<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02601157</url>
  </required_header>
  <id_info>
    <org_study_id>HOST-IDEA trial</org_study_id>
    <nct_id>NCT02601157</nct_id>
  </id_info>
  <brief_title>Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis - Coronary Intervention With Next Generation Drug-Eluting Stent Platforms and Abbreviated Dual Antiplatelet Therapy (HOST-IDEA) Trial</brief_title>
  <acronym>HOST-IDEA</acronym>
  <official_title>Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis - Coronary Intervention With Next Generation Drug-Eluting Stent Platforms and Abbreviated Dual Antiplatelet Therapy (HOST-IDEA) Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>B. Braun Korea Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We had little experience in coronary intervention with recently introduced newer drug-eluting
      stent (DES) platforms, despite great anticipation, and optimal duration of dual antiplatelet
      therapy (DAPT) for these stent systems still needs to be established.

      With a 2x2 factorial design for patients of stable angina or silent ischemia, the
      investigators formulate a head-to-head randomized comparison between sirolimus-eluting Orsiro
      stent with biodegradable polymer and polymer-free stent platform with the same
      antiproliferative agent, Coroflex ISAR stent system. At the same time, clopidogrel treatment
      is added to aspirin during the 3-months period after the stenting, and this abbreviated
      duration of DAPT will be compared with conventional 1-year mandatory DAPT regimen in a 1:1
      randomized stratification. 1-year target lesion failure (TLF) as a composite of cardiac
      death, target vessel related myocardial infarction and clinically driven target lesion
      revascularization will be identified as a primary efficacy outcome. And in addition to TLF,
      definite or probable stent thrombosis and major bleeding events will also be counted as a
      composite outcome of net adverse clinical events (NACEs) to comprehensively adjudicate the
      efficacy and safety outcomes according to the difference of DAPT duration.

      With this trial, you will be able to get clear insight on the behavior of newer DES
      platforms. Reference data for the shortened mandatory DAPT regimen will also be delineated in
      the selected patients, and it might be helpful to those who need it.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Every antiplatelet-naïve patient undergoing an elective procedure will be given 300 mg
      aspirin and loading dose of one of P2Y12 receptor inhibitors (e.g., 600 mg clopidogrel, 60 mg
      prasugrel or 180 mg ticagrelor) preferably ≥2 hours before the intervention. These loading
      doses can be waived for chronic antiplatelet users, and prasugrel or ticagrelor can be used
      instead of clopidogrel. Choice for P2Y12 inhibitors will be left to responsible physicians'
      discretion, and this decision will be based on the patient/lesional characteristics.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2015</start_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>TLF (target lesion failure)</measure>
    <time_frame>post-stenting 12 months</time_frame>
    <description>composite end-point of cardiac death, target lesion-related non-fatal myocardial infarction, clinically-driven target lesion revascularization</description>
  </primary_outcome>
  <primary_outcome>
    <measure>NACEs (net adverse clinical events)</measure>
    <time_frame>post-stenting 12 months</time_frame>
    <description>TLF + definite or probable stent thrombosis, major bleeding</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>definite or probable stent thrombosis and major bleeding</measure>
    <time_frame>post-stenting 12 months</time_frame>
    <description>stent thrombosis or major bleeding as a safety measure</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">2152</enrollment>
  <condition>Stable Angina</condition>
  <condition>Unstable Angina</condition>
  <condition>Non-ST Segment Elevation Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Orsiro SES/3-months DAPT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>As an one of experimental arms in 2x2 factorial design, patients allocated to this group will be implanted with Orisro sirolimus-eluting stents for their coronary lesions, and then will be followed with 3-month dual antiplatelet therapy (DAPT) schedule.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Orsiro SES/1-year DAPT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>As an one of comparator arms in 2x2 factorial design, patients allocated to this group will be implanted with Orisro sirolimus-eluting stents for their coronary lesions, and then will be followed with 1-year dual antiplatelet therapy (DAPT) schedule.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CX-ISAR/3-months DAPT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>As an one of experimental arms in 2x2 factorial design, patients allocated to this group will be implanted with Coroflex ISAR (CX-ISAR) sirolimus-eluting stents for their coronary lesions, and then will be followed with 3-month dual antiplatelet therapy (DAPT) schedule.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CX-ISAR/1-year DAPT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>As an one of comparator arms in 2x2 factorial design, patients allocated to this group will be implanted with Coroflex ISAR (CX-ISAR) sirolimus-eluting stents for their coronary lesions, and then will be followed with 1-year dual antiplatelet therapy (DAPT) schedule.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CX-ISAR</intervention_name>
    <description>Patients with significant coronary lesions will be treated with this contemporary stent platform. This stent platform has a thin-strut cobalt-chromiun alloy backbone, no polymer, microporous surface.</description>
    <arm_group_label>CX-ISAR/3-months DAPT</arm_group_label>
    <arm_group_label>CX-ISAR/1-year DAPT</arm_group_label>
    <other_name>Coroflex ISAR sirolimus-eluting stents</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Orsiro</intervention_name>
    <description>Patients with significant coronary lesions will be treated with this contemporary stent platform. This stent platform has a thin-strut cobalt-chromiun alloy backbone, abluminal coatings with biodegradable polymer.</description>
    <arm_group_label>Orsiro SES/3-months DAPT</arm_group_label>
    <arm_group_label>Orsiro SES/1-year DAPT</arm_group_label>
    <other_name>Orsiro sirolimus-eluting stents</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3-months DAPT</intervention_name>
    <description>Contrast to the conventional 1-year DAPT, patients in this group will be followed with 3-months DAPT schedule after the stenting</description>
    <arm_group_label>Orsiro SES/3-months DAPT</arm_group_label>
    <arm_group_label>CX-ISAR/3-months DAPT</arm_group_label>
    <other_name>Aspirin + P2Y12 inhibitor (clopidogrel/prasugrel/ticagrelor) for 3-months schedule after the coronary stenting</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1-year DAPT</intervention_name>
    <description>Patients in this group will be followed with the conventional 1-year DAPT schedule after the stenting</description>
    <arm_group_label>Orsiro SES/1-year DAPT</arm_group_label>
    <arm_group_label>CX-ISAR/1-year DAPT</arm_group_label>
    <other_name>Aspirin + P2Y12 inhibitor (clopidogrel/prasugrel/ticagrelor) for 1-year schedule after the coronary stenting</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with de novo stenotic lesions who are suitable for coronary stenting with
             drug-eluting stent

        Exclusion Criteria:

          -  1. High risk profiles for ischemic adverse events such as A. ST-segment elevation
             myocardial infarction (STEMI) B. Patients with cardiogenic shock or concomitant severe
             decompensated heart failure C. Myocardial infarction or stent thrombosis in spite of
             the maintenance of antiplatelet therapy D. Restenosis in stented segments or previous
             sites of balloon angioplasty 2. Patients who cannot follow allocated DAPT schedule due
             to the planned surgery or elective procedure within 3 months after the stenting 3.
             Recent history of major surgery or evident events of gastrointestinal bleeding within
             1 month from the procedure 4. Patients on anticoagulation therapy with warfarin or
             other anticoagulants 5. Life expectancy less than 1 year (such as malignancies or
             other chronic systemic diseases) 6. Pregnant women 7. Past history of allergy or other
             contraindications for the following medications/materials: aspirin, clopidogrel,
             heparin, cobalt chromium, sirolimus
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyo-Soo Kim, M.D., Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hyo-Soo Kim, M.D., Ph.D.</last_name>
    <phone>82-2-2072-2226</phone>
    <email>hyosoo@snu.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Busan Paik Hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tae-Hyun Yang, M.D., PhD</last_name>
      <email>yangthmd@naver.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kosin University Gospel Hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tae-Joon Cha, M.D., PhD</last_name>
      <email>chatjn@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>SoonChunHyang University Cheonan Hospital</name>
      <address>
        <city>Cheonan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seung Jin Lee, M.D., PhD</last_name>
      <email>drlsj3@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hospital</name>
      <address>
        <city>Gwangju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Myung-Ho Jeong, M.D., PhD</last_name>
      <email>mhjeong@chonnam.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gwangju Christian Hospital</name>
      <address>
        <city>Gwangju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seung Uk Lee, M.D., PhD</last_name>
      <email>cardiosu@hanmail.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ewha Womans University Medical Center Mokdong Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wook Bum Pyun, MD. PhD.</last_name>
      <email>pwb423@ewha.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hallym University Kangdong Sacred Heart Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kyu-Rock Han, MD. PhD.</last_name>
      <email>krheart@hallym.or.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kangnam Sacred Heart Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Namho Lee, M.D., PhD</last_name>
      <email>namholee@hallym.or.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jin Won Kim, M.D., PhD</last_name>
      <email>kjwmm@korea.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kyung Hee University Hospital at Gangdong</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jin-Man Cho, M.D., PhD</last_name>
      <email>aceri@medimail.co.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyo-Soo Kim, M.D., PhD</last_name>
      <phone>82-2-2072-2226</phone>
      <email>hyosoo@snu.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ajou University Hospital</name>
      <address>
        <city>Suwon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Myeong-Ho Yoon, M.D., PhD</last_name>
      <email>yoonmh65@hanmail.net</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 7, 2015</study_first_submitted>
  <study_first_submitted_qc>November 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2015</study_first_posted>
  <last_update_submitted>May 26, 2017</last_update_submitted>
  <last_update_submitted_qc>May 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Hyo-Soo Kim</investigator_full_name>
    <investigator_title>Director of Cardiac Catheterization Laboratory &amp; Coronary Intervention</investigator_title>
  </responsible_party>
  <keyword>stent</keyword>
  <keyword>polymer</keyword>
  <keyword>antiplatelet therapy</keyword>
  <keyword>clopidogrel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Angina Pectoris</mesh_term>
    <mesh_term>Angina, Stable</mesh_term>
    <mesh_term>Angina, Unstable</mesh_term>
    <mesh_term>Coronary Stenosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Prasugrel Hydrochloride</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

